A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs CV 301 (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 15 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2020.
- 11 Jul 2018 According to a Bavarian Nordic media release, first patient has been dosed in this study.
- 11 Jul 2018 Status changed from not yet recruiting to recruiting, according to a Bavarian Nordic media release.